Publication and non-publication of drug trial results: a 10-year cohort of trials in Norwegian general practice.

BMJ Open

Faculty of Medicine, Department of General Practice, Institute of Health and Society, University of Oslo, Oslo, Norway.

Published: April 2016

Objectives: Previously, we identified a 10-year cohort of protocols from applications to the Norwegian Medicines Agency 1998-2007, consisting of 196 drug trials in general practice. The aim of this study was to examine whether trial results were published and whether trial funding and conflicts of interest were reported.

Design: Cohort study of trials with systematic searches for published results.

Setting: Clinical drug trials in Norwegian general practice.

Methods: We performed systematic literature searches of MEDLINE, Embase and CENTRAL to identify publications originating from each trial using characteristics such as test drug, comparator and patient groups as search terms. When no publication was identified, we contacted trial sponsors for information regarding trial completion and reference to any publications.

Main Outcome Measures: We determined the frequency of publication of trial results and trial characteristics associated with publication of results.

Results: Of the 196 trials, 5 were never started. Of the remaining 191 trials, 71% had results published in a journal, 11% had results publicly available elsewhere and 18% of trials had no results available. Publication was more common among trials with an active comparator drug (χ(2) test, p=0.040), with a larger number of patients (total sample size≥median, p=0.010) and with a longer trial period (duration≥median, p=0.025). Trial funding was reported in 85% of publications and increased over time, as did reporting of conflicts of interest among authors. Among the 134 main journal articles from the trials, 60% presented statistically significant results for the investigational drug, and the conclusion of the article was favourable towards the test drug in 78% of papers.

Conclusions: We did not identify any journal publication of results for 29% of the general practice drug trials. Trials with an active comparator, larger and longer trials were more likely to be published.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4838717PMC
http://dx.doi.org/10.1136/bmjopen-2015-010535DOI Listing

Publication Analysis

Top Keywords

trials
12
general practice
12
drug trials
12
trial
10
drug
8
10-year cohort
8
trials norwegian
8
norwegian general
8
trial funding
8
conflicts interest
8

Similar Publications

Experience-driven suppression of irrelevant distractor locations is context dependent.

Atten Percept Psychophys

January 2025

Department of Psychology, The Ohio State University, 225 Psychology Building, 1835 Neil Ave, Columbus, OH, 43210, USA.

Humans can learn to attentionally suppress salient, irrelevant information when it consistently appears at a predictable location. While this ability confers behavioral benefits by reducing distraction, the full scope of its utility is unknown. As people locomote and/or shift between task contexts, known-to-be-irrelevant locations may change from moment to moment.

View Article and Find Full Text PDF

Safety and efficacy of tirofiban in the endovascular treatment of intracranial aneurysms: a systematic evaluation and meta-analysis.

Neurosurg Rev

January 2025

Hengyang Key Laboratory of Hemorrhagic Cerebrovascular Disease, Department of Neurosurgery, the Second Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, 421000, Hunan, China.

Patients with intracranial aneurysms (IA) undergoing endovascular treatment face varying risks and benefits when tirofiban is used for thromboprophylaxis during surgery. Currently, there is a lack of high-level evidence summarizing this information. This study aims to conduct a systematic review and meta-analysis to evaluate the efficacy and safety of tirofiban during endovascular treatment of IA.

View Article and Find Full Text PDF

Background And Objective: Limited information is available on the pharmacokinetics of rifampicin (RIF) along with that of its active metabolite, 25-deacetylrifampicin (25-dRIF). This study aimed to analyse the pharmacokinetic data of RIF and 25-dRIF collected in adult patients treated for tuberculosis.

Methods: In adult patients receiving 10 mg/kg of RIF as part of a standard regimen for drug-susceptible pulmonary tuberculosis enrolled in the Opti-4TB study, plasma RIF and 25-dRIF concentrations were measured at various occasions.

View Article and Find Full Text PDF

Background: Concurrent exercise (CE), an emerging exercise modality characterized by sequential bouts of aerobic (AE) and resistance exercise (RE), has demonstrated acute benefits on executive functions (EFs) and neuroelectric P3 amplitude. However, the effect of acute CE on inhibitory control, a sub-component of EFs, and P3 amplitude remains inconclusive. Moreover, exploring the mechanisms underlying the effects of acute exercise on EFs contributes to scientific comprehension, with lactate recognized as a crucial candidate positively correlated with EFs.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!